Table 3. Published Reports from Individual Health Plans.
| Reference | Reporting Site | Diagnosis Years | No. Women with Invasive Breast Cancer | No. (%) women not evaluated for HER2 | % HER2 positive1 | No. (%) women who received trastuzumab without a documented positive HER2 result | No. (%) HER2 positive women who received trastuzumab |
|---|---|---|---|---|---|---|---|
| Stark (2004) 27 | Henry Ford Health System | 1999-2000 | 451 | 212 (48%) | Not reported | Not reported | Not reported |
| Onitilo (2009) 28 | Marshfield Clinic | 1998-2005 | 1767 | 612 (35%)2 | 201 (18%) | Not reported | Not reported |
| Barron (2009) 29 | Three commercial health plans | 2005-mid 2006 | 322 | 6 (2%) | 72 (21%) | 1/52 (2%) | 39/45 (87%) stage II or higher |
| Webster (2010) 30 | SW Wales Cancer Network (UK) | 2006-2007 | 453 | 61 (13.5%) | 47 (10%) | Not reported | 34/47 (72.3%) |
| Webster (2010) 30 | SW Wales Cancer Network (UK) – Cardiff & Vale only | 2005-2008 | 121 | Not reported | 121 (100%)3 | Not reported | 93/121 (76.8%) |
| Coulson (2010) 31 | North Trent Cancer Network (UK) | Sept. 2007 – Aug. 2008 | 13194 | Not reported | 199 (15%) | Not reported | 133/199 (67%) |
| Haas (2011)32 | Aetna | July 2006 – June 2007 | 775 | 24 (3.1%) | 137 (18%) | 25/104 (24%) | 79/137 (57.7%) stage I, II, or III |
| Goddard (2011)33 | Kaiser Permanente Northwest | 1998-2007 | 3054 | 579 (19%) | 496 (14%) | 26/134 (19%) | 19/32 (60%) distant metastatic 28/41 (68%) regional (after 2005) 35/79 (44%) localized (after 2005) |
1
of those evaluated for HER2 status.
2
women were not tested for ER/PR or HER2. The data for HER2 alone were not reported separately.
3
Selected for the study on these criteria.
4
metastatic breast cancer cases were excluded